Abstract: Chromosomal instability (CIN) of gastric cancer is correlated with distinct outcomes. This study aimed to investigate the role of computed tomography (CT) imaging traits in predicting the CIN status of gastric cancer. We screened 443 patients in the Cancer Genome Atlas gastric cancer cohort to filter 40 patients with complete CT imaging and genomic data as the training cohort. CT imaging traits were subjected to logistic regression to select independent predictors for the CIN status. For the validation cohort, we prospectively enrolled 18 gastric cancer patients for CT and tumor genomic analysis. The imaging predictors were tested in the validation cohort using receiver operating characteristic curve (ROC) analysis. Thirty patients (75%) in the training cohort and 9 patients (50%) in the validation cohort had CIN subtype gastric cancers. Smaller tumor diameter (p = 0.017) and acute tumor transition angle (p = 0.045) independently predict CIN status in the training cohort. In the validation cohort, acute tumor transition angle demonstrated the highest accuracy, sensitivity, and specificity of 88.9%, 88.9%, and 88.9%, respectively, and areas under ROC curve of 0.89. In conclusion, this pilot study showed acute tumor transition angle on CT images may predict the CIN status of gastric cancer.
Introduction
Gastric cancer is one of the most common and aggressive solid malignancies worldwide, with the highest incidence in Asia [1, 2] . Patients undergoing standard treatment (i.e., surgical resection plus adjuvant chemotherapy or radiochemotherapy) have high rates of tumor recurrence (20%-40%) [3, 4] . The heterogeneity in clinical outcomes in gastric cancer is consistent with other solid tumors, and genomic analysis has repeatedly shown that tumors are molecularly diverse [5] . Therapies specifically targeting key molecular features can have clinical outcomes beyond those of traditional standard therapies [5, 6] . Conventional Lauren [7] and World Health Organization [8] classifications are based on histopathologic features and have limited implications in guiding personalized therapy for gastric cancer patients [9] . More recently, the Cancer Genome Atlas (TCGA) research group developed a molecular classification system based on gene expression profiling for gastric cancer. It emphasizes a molecular pathogenesis perspective, providing a potential roadmap for targeted therapy [9] . Among the four TCGA subtypes-Epstein-Barr virus (EBV)-positive, microsatellite unstable, chromosomal instability (CIN), and genomically stable-CIN subtype gastric cancer accounts for nearly half of all gastric cancer cases [9] . The CIN status is defined as a high degree of somatic copy number variation by gaining or losing chromosomes [10] . Traditionally, the CIN status of tumors are detected by molecular cytogenetic techniques such as comparative genomic hybridization, polymerase chain reaction, flow cytometry, or single nucleotide polymorphism arrays-based methods [11] . In daily clinical practice, these complex genomic analysis techniques may not provide timely information for decision making in cancer treatment, and tumor specimen is not always available. Besides, CIN is a complex, heterogenous, and ongoing process that initiates and drives oncogenesis, and the profile of CIN may not be completely delineated by traditional methods. If CIN subtype gastric cancer could be predicted using clinical, imaging, or histopathologic data collected in the routine evaluation and work-up of gastric cancer patients, they may provide rapid and complementary information before genomic analysis results [12] .
Radiogenomics (the science of multiscale data fusion) is a powerful, robust, and scalable tool that has been applied across different tumor types and imaging modalities to address many crucial questions in oncology [13] . It has been used to create "association maps" between large-scale multilevel genomic data and image features from clinical imaging to identify clinically significant prognostic and predictive biomarkers. It has also been used to define molecular patterns associated with particular image phenotypes in different imaging modalities and tumor types. Radiogenomics links and validates associations between imaging signatures, clinical findings, and molecular pathogenesis [14] . Computed tomography (CT) is a routine preoperative evaluation modality in gastric cancer patients. With the development of isotropic imaging and multiplanar reconstruction, early gastric cancer can now be detected through multidetector CT, with a reported detection rate of 90% [15] . The TNM staging system is a widely used cancer staging system based on the tumor extent, the lymph node spread, and the presence of metastasis [16] . Studies have mainly focused on the key components of the TNM staging system to improve diagnostic accuracy. Little attention has been paid to other imaging traits such as tumor morphology, texture, or contrast enhancement pattern, which do not contribute to the TNM staging system. Through radiogenomic analysis, imaging traits that provide additional information can be extracted during routine imaging examination without additional costs. No study has investigated the radiological phenotypes associated with clinically significant genomic signatures in gastric cancer. Whether radiogenomic features from CT imaging can be used to identify CIN subtype gastric cancer remains a critical and unaddressed question.
In this study, we aimed to investigate the role of CT imaging traits in predicting the CIN status of gastric cancer.
Results

Training Cohort and Imaging Predictors
We screened 443 patients in the TCGA gastric cancer cohort and selected 43 patients with complete CT imaging, genomic, and clinical data. We further excluded three patients from the training cohort: two for small tumor diameter (<1 cm) and one for predominant distal esophageal tumor. Thus, the final training cohort comprised 40 patients: 35 men and 5 women ( Table 1 ). The median age was 68 years (range, 36-79). The median tumor diameter was 5.4 cm (range, 2.8-12.5). None of the patients had early gastric cancer, defined as tumor limited to the mucosa or submucosa regardless of lymph node status, according to the Japanese Gastric Cancer Association [17] 
Validation Cohort
The validation cohort included 18 patients, consisting of 11 men and 7 women ( Table 1 ). The median age was 68 years (range, 47-87). The median tumor diameter was 3.7 cm (range, 1.7-11.6). The tumor diameter of the validation cohort was significantly smaller than that of training cohort (p = 0.01). No significant differences were observed in TNM staging between the validation and training cohorts. Using the Lauren system, the histologic type of gastric cancer was classified as intestinal type in 7, diffuse type in 6, and mixed type in 5 patients. In the validation cohort, 9 patients had CIN subtype gastric cancer (Figure 1 ). The CIN subtype gastric cancer was predominantly of the Lauren intestinal type, and the non-CIN subtype gastric cancer was predominantly of the Lauren diffuse type. Variance in the degree of aneuploidy (i.e., copy number loss or gain) was observed in the CIN subtype gastric cancers. The median number of aneuploidy genes was 63 (range, 25 to 200). 
Diagnostic Accuracy of Imaging Predictors
The imaging predictors identified from the training cohort were tested in the validation cohort. A tumor diameter cutoff value of ≤7.2 cm was obtained from the training cohort using receiver operating characteristic curve (ROC) analysis. The diagnostic accuracy of imaging predictors was evaluated by ROC analysis in the validation cohort. The areas under the receiver operating characteristic curve (AUC) were 0.89 (95% CI, 0.72-1.00) for acute tumor transition angle and 0.67 (95% CI, 0.41-0.93) for tumor diameter ≤7.2 cm in the validation cohort ( Figure 2 ). As the more accurate imaging predictor of the CIN status of gastric cancer, acute tumor transition angle achieved an accuracy, sensitivity, and specificity of 88.9%, 88.9%, and 88.9% in the validation cohort as detailed in Table 3 . Examples of imaging traits analysis of CIN and non-CIN gastric cancers are demonstrated in Figures 3 and 4 , respectively. 
The imaging predictors identified from the training cohort were tested in the validation cohort. A tumor diameter cutoff value of ≤7.2 cm was obtained from the training cohort using receiver operating characteristic curve (ROC) analysis. The diagnostic accuracy of imaging predictors was evaluated by ROC analysis in the validation cohort. The areas under the receiver operating characteristic curve (AUC) were 0.89 (95% CI, 0.72-1.00) for acute tumor transition angle and 0.67 (95% CI, 0.41-0.93) for tumor diameter ≤7.2 cm in the validation cohort ( Figure 2 ). As the more accurate imaging predictor of the CIN status of gastric cancer, acute tumor transition angle achieved an accuracy, sensitivity, and specificity of 88.9%, 88.9%, and 88.9% in the validation cohort as detailed in Table 3 Non-chromosomal instability subtype gastric cancer in a 68-year-old male who underwent preoperative contrast-enhanced computed tomography. (a) portal venous phase axial and (b) arterial phase sagittal images showed extensive circumferential wall thickening involving the gastric fundus, cardia and body with the largest diameter of 6.6 cm. The tumor had obtuse tumor transition angle (arrow in a), ill-defined margin and infiltrative shape in morphology. Because of the peri-gastric stranding densities, the lesion was also defined to have "serosal invasion" imaging trait (arrowheads in a and b), which was later confirmed by histopathology analysis.
Discussion
Our study showed that the two imaging traits-smaller tumor diameter and acute tumor transition angle-independently predicted the CIN status of gastric cancer in the training cohort. In the independent validation cohort, the imaging trait of acute tumor transition angle was the more accurate imaging predictor, with sensitivity and specificity of 88.9% and 88.9%, respectively; this trait may noninvasively predict the CIN status of gastric cancer. Consistent with the findings for our prospective validation cohort, CIN subtype gastric cancer accounted for approximately 50% of the study cohort of TCGA classification study [9] . The CIN subtype has better responses to adjuvant chemotherapy, whereas the microsatellite unstable and genomically stable subtype have only moderate benefits and no benefits from adjuvant chemotherapy, respectively [18] . By knowing the CIN status of gastric cancer, a personalized adjuvant treatment strategy including conventional Non-chromosomal instability subtype gastric cancer in a 68-year-old male who underwent preoperative contrast-enhanced computed tomography. (a) portal venous phase axial and (b) arterial phase sagittal images showed extensive circumferential wall thickening involving the gastric fundus, cardia and body with the largest diameter of 6.6 cm. The tumor had obtuse tumor transition angle (arrow in a), ill-defined margin and infiltrative shape in morphology. Because of the peri-gastric stranding densities, the lesion was also defined to have "serosal invasion" imaging trait (arrowheads in a and b), which was later confirmed by histopathology analysis.
Our study showed that the two imaging traits-smaller tumor diameter and acute tumor transition angle-independently predicted the CIN status of gastric cancer in the training cohort. In the independent validation cohort, the imaging trait of acute tumor transition angle was the more accurate imaging predictor, with sensitivity and specificity of 88.9% and 88.9%, respectively; this trait may noninvasively predict the CIN status of gastric cancer. Consistent with the findings for our prospective validation cohort, CIN subtype gastric cancer accounted for approximately 50% of the study cohort of TCGA classification study [9] . The CIN subtype has better responses to adjuvant chemotherapy, whereas the microsatellite unstable and genomically stable subtype have only moderate benefits and no benefits from adjuvant chemotherapy, respectively [18] . By knowing the CIN status of gastric cancer, a personalized adjuvant treatment strategy including conventional (a) ), ill-defined margin and infiltrative shape in morphology. Because of the peri-gastric stranding densities, the lesion was also defined to have "serosal invasion" imaging trait (arrowheads in (a,b)), which was later confirmed by histopathology analysis.
Our study showed that the two imaging traits-smaller tumor diameter and acute tumor transition angle-independently predicted the CIN status of gastric cancer in the training cohort. In the independent validation cohort, the imaging trait of acute tumor transition angle was the more accurate imaging predictor, with sensitivity and specificity of 88.9% and 88.9%, respectively; this trait may noninvasively predict the CIN status of gastric cancer. Consistent with the findings for our prospective validation cohort, CIN subtype gastric cancer accounted for approximately 50% of the study cohort of TCGA classification study [9] . The CIN subtype has better responses to adjuvant chemotherapy, whereas the microsatellite unstable and genomically stable subtype have only moderate benefits and no benefits from adjuvant chemotherapy, respectively [18] . By knowing the CIN status of gastric cancer, a personalized adjuvant treatment strategy including conventional chemotherapy and target therapy could potentially be tailored for gastric cancer patients based on their radiogenomic CT profile.
The Borrmann classification system is a morphologic classification of advanced gastric cancer based on endoscopy or macroscopic pathology examination; it provides a simple and valuable prediction of lymph node metastasis and survival [19, 20] . The CIN subtype gastric cancers in the present study were predominantly of the intestinal type according to Lauren classification, which is in line with the literature data [9] . Although the Lauren intestinal type had been reported to be associated with less advanced Borrmann morphology (i.e., more likely acute tumor transition angle) [9, 21] , the association of Borrmann classification with CIN subtype gastric cancer could not be demonstrated in our study. Besides, it remains unaddressed whether the transition angle changes as the tumor grows, because our training and validation cohorts comprised mostly advanced gastric cancers. The only one CIN subtype gastric cancer showing obtuse tumor transition angle had a relatively low number of aneuploidy genes of 34. However, we could not exclude the patient from the validation cohort because the patient was not an outliner in degree of aneuploidy. The relationship between the degree of aneuploidy and tumor transition angle was undetermined due to limited sample size of this study. On the other hand, the Lauren diffuse type gastric cancer is enriched in the genomically stable subtype gastric cancer of TCGA classification system [9] . Zhou et al. had demonstrated that abnormal expression of E-cadherin, which is a major adhesion molecule in the cell-cell junction, correlated with the Lauren diffuse type gastric cancer and more infiltrative morphology (Borrmann type III and IV) [22] .
EBV-associated gastric cancers account for approximately 9% of all gastric cancers [23] . They are characterized by high EBV burden and DNA promoter hypermethylation [9] . A study of 10 EBV-associated gastric cancer patients showed that location in the upper gastric region, large thickness-to-width ratio, or bulky mass projecting from the wall were CT features of EBV-associated gastric cancer [24] . In our TCGA training cohort, two patients had EBV-positive subtype gastric cancer, and both of the tumors were located in the upper gastric body. However, further CT imaging feature analysis of EBV-positive subtype gastric cancer was precluded due to limited patient number.
To accurately extract imaging traits from CT images, the patients with smaller tumor diameter (<1 cm) were excluded from this study, which may account for the relatively large cutoff value of 7.2 cm obtained from the training cohort by ROC analysis. The diagnostic accuracy was unsatisfactory based on tumor diameter in the validation cohort, plausibly because of the significant difference in tumor diameter between the training and validation cohort. Future study of larger sample size may provide a more optimal cutoff value for tumor diameter in predicting the CIN status of gastric cancer.
Tsurumaru et al. demonstrated the association between gastric cancer histopathologic types and the contrast enhancement pattern on dynamic contrast-enhanced CT images [25, 26] . In our study, no association was observed between the double-layered enhancement pattern and CIN status. Consistent with our result, Lauren diffuse type gastric cancer (usually non-CIN subtype gastric cancer) frequently showed a double-layered pattern on arterial phase images and a single-layered pattern on delayed phase images [25] .
The novel concept of radiogenomics provides a connection between imaging traits and genetic information of cancers [13] . In the era of precision medicine, there is an increasing need to classify and treat cancers on a molecular basis because the clinical outcomes and treatment response may vary even if the cancers are histologically similar [27] . Although the advancement of high-throughput analysis has facilitated more rapid and lower cost genomics data acquirement [14] , the inherent limitation is three-fold. First, genomic profiles require adequate tumor tissue, specialized equipment, and technical expertise. Second, surgical or image-guided tumor biopsy is not always feasible in cancer patients due to risks and possible complications associated with the biopsy procedure. Third and most importantly, a tumor may have different internal components with distinct gene expression patterns (i.e., intratumoral heterogeneity) [28] . Thus, tumor specimens only represent a small portion of the tumor rather than the whole tumor. Noninvasive imaging examinations, which are routinely performed for clinical staging, have the potential to provide overall perspectives of the tumor and demonstrate intratumoral heterogeneity. It will be helpful if we can correlate imaging traits (i.e., imaging phenotype or radiophenotype) to certain genetic subtypes or gene expression patterns of cancers [29] . Radiogenomic features have been demonstrated to be associated with the luminal B subtype of breast cancer [30] or the VHL gene mutation in clear cell renal cell carcinoma [31] .
Serum biomarker is another potential approach to predict the CIN status of gastric cancer. CIN in plasma or serum cell-free DNA has been used to detect ovarian cancer or prostate cancer [32, 33] . In gastric cancer, a study had demonstrated plasma DNA concentration as diagnostic biomarker by quantifying plasma cell-free DNA [34] . However, it is still unclear whether CIN in serum cell-free DNA correlates with the CIN subtype gastric cancer of TCGA classification, and it may be a feature direction of research. The potential serum biomarker may be a complement to our CT imaging predictor and enhance the accuracy in predicting CIN subtype gastric cancer.
This study has several limitations. First, although a prospective validation cohort was included, a retrospective cohort was used for training, and both cohorts have small sample sizes. The preliminary results of this study warrant further validation in a larger gastric cancer cohort with surrogate profiles of CIN, such as an immunohistochemistry panel of MLH1, p53, and EBER staining [35] , or CIN70 signature-70 genes that correlate with high levels of aneuploidy [36, 37] . Second, the majority of enrolled patients had resectable advanced gastric cancers in the current report. Further study should include more patients with more unresectable tumors or early gastric cancers, or even in CIN animal models, to test the generalizability of this pilot finding. Third, we determined tumor morphology on multiplanar reconstruction images. Although these images allow radiologists to evaluate target lesions in different orientations, the partial volume effect may still lead to the incorrect interpretation of morphologic imaging traits. Future CT studies with three-dimensional reformatted virtual gastroscopy may provide more precise and global views of gastric cancer when interpreting imaging traits. Lastly, although CT texture features might correlate with immunochemical biomarkers such as E-cadherin, Ki67, VEGFR2, and EGFR in gastric cancer [38] , the large feature numbers might cause false-discovery in our limited sample sizes. Nevertheless, our initial report is the first study utilizing the radiogenomic approach to analyze the molecular subtype of gastric cancer. Radiogenomic analysis of gastric cancer including the analysis of CT texture features may be a future research direction.
Materials and Methods
Study Patients and Data Collection
This study was designed as a disease landscape study with no prespecified hypothesis. The institutional review board approved the protocol of this study (project number: 201601916B0C601), which had both retrospective and prospective components. A waiver of consent was obtained for the retrospective phase, which involved the extraction of imaging traits from a publicly available database. For the prospective phase, informed consent was obtained from participants in a tertiary referral center. For patient enrolment, a dedicated gastric cancer interdisciplinary team screened patents through image examination and molecular analysis of tissue specimens, as described herein.
Training Cohort
The public data portal of the TCGA provides public data of a cohort of gastric cancer patients containing complete genomic sequencing and clinical data (https://cancergenome.nih.gov). The Cancer Imaging Archive data set contains publicly available CT images of a subset of TCGA cohort patients (http://www.cancerimagingarchive.net). We selected gastric cancer patients with preoperative CT images from the TCGA cohort as the training cohort. To accurately extract imaging traits from CT images, the patients with tumor diameter <1 cm on CT images were excluded.
Imaging Traits Evaluation
Fourteen qualitative and two quantitative imaging traits were defined and analyzed for their association with the CIN status of gastric cancer (Table 4 and Figure 5 ). The "tumor shape" imaging trait was defined according to the Borrmann classification system (a morphologic classification of advanced gastric cancer) [20] . Two radiologists (Ying-Chieh Lai and Gigin Lin with 3 and 12 years of oncology imaging experience, respectively) independently reviewed CT images of all patients and were blinded to their clinical variables and genomic analysis results. Imaging traits extracted from CT images were evaluated on the picture archiving and communication system. In case of discrepancy in interpretation, the final results of imaging traits were based on a consensus between the two radiologists. 
Validation Cohort
From May 2016-April 2017, consecutive gastric cancer patients from our center were screened and included in the validation cohort. The inclusion criteria were (1) age of 20-80 years; (2) histologically confirmed adenocarcinoma of the stomach; and (3) tumors considered resectable by gastric cancer interdisciplinary team. The exclusion criteria were (1) tumor diameter <1 cm on CT images; (2) prior gastric surgery; and (3) prior neoadjuvant chemotherapy or chemoradiotherapy. The patients underwent preoperative CT images within 14 days of surgery in accordance with the institutional CT protocol for gastric cancer. Histopathologic and genomic analysis of the gastric cancer specimens obtained via surgical resection was performed. 
From May 2016-April 2017, consecutive gastric cancer patients from our center were screened and included in the validation cohort. The inclusion criteria were (1) age of 20-80 years; (2) histologically confirmed adenocarcinoma of the stomach; and (3) tumors considered resectable by gastric cancer interdisciplinary team. The exclusion criteria were (1) tumor diameter <1 cm on CT images; (2) prior gastric surgery; and (3) prior neoadjuvant chemotherapy or chemoradiotherapy. The patients underwent preoperative CT images within 14 days of surgery in accordance with the institutional CT protocol for gastric cancer. Histopathologic and genomic analysis of the gastric cancer specimens obtained via surgical resection was performed.
Imaging Analysis
All CT examinations of validation cohort were performed using 320-detector row CT (Aquilion ONE; Toshiba Medical Systems, Otawara, Japan). Oral contrast medium of 500 mL water was administered before imaging to distend the stomach, and intravenous contrast medium of 100 mL iohexol (350 mg iodine per millilitre, Omnipaque 350; GE Healthcare, Princeton, NJ, USA) was administrated using a power injector, with an injection rate of 3 mL/s. Multiphase (arterial and portal venous phases) contrast-enhanced CT imaging was performed as per the institutional standard CT protocol for gastric cancer. Multiphase CT imaging was performed after an empirical delay from initiation of contrast medium injection. The delay time was 25 and 70 s for arterial and portal venous phase imaging, respectively. The arterial phase scan focused on the stomach, and portal venous phase imaging was performed from the abdomen to pelvis. Coronal and sagittal multiplanar reconstruction images were used for more precise tumor detection and invasion depth evaluation. CT scan parameters were as follows: 120 kVp and automatic tube current modulation and image reconstruction to 5-mm thickness and at 5-mm intervals for viewing on a picture archiving and communication system. Two radiologists (Ying-Chieh Lai and Gigin Lin) who were blinded to the genomic analysis results independently tested predictors of CIN subtype gastric cancer on the validation cohort. The final results were based on a consensus between the two radiologists.
Histopathologic and Genomic Analysis
A gastrointestinal pathology specialist (Ren-Chin Wu, 12 years of experience) evaluated all haematoxylin and eosin-stained tissue slides of the validation cohort and provided information on the Lauren histologic type and the local invasion and lymph node metastasis status. Patients were classified to CIN subtype and non-CIN subtype according to the TCGA system [9] , independent to the clinical information and CT imaging results. Genomic DNA was extracted from Formalin-fixed paraffin-embedded (FFPE) tumor samples using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany); DNA was quantified using the Quant-iT dsDNA HS Assay (Invitrogen, Waltham, MA, USA). Genomic DNA (80 ng) was amplified using four pools of 15,992 primer pairs (Ion AmpliSeq Comprehensive Cancer Panel, Life Technologies, Carlsbad, CA, USA) to target the coding exon regions of 409 cancer-related genes, which covered the TP53/cell cycle, JAK/STAT, Ras/PI3K, Wnt, receptor tyrosine kinase, chromatin remodelling, DNA repair, TGFβ, and cadherin signaling. We classified gastric cancer patients by tumor based on whether the proportion of altered genes was high or low. The 409 genes (including both oncogenes and tumor suppressor genes) in gastric cancer tumor tissue were sequenced (Appendix A Table A1 ).
Statistical Analysis
All data were analyzed using SPSS version 25 (Armonk, NY, USA). Categorical variables were compared between groups using the chi-square or Fisher's exact test, and continuous variables were compared using non-parametric Mann-Whitney U test. Univariate and multivariate logistic regression with stepwise procedure was used to identify the independent imaging predictors of CIN subtype gastric cancer. The tumor diameter was dichotomized by cutoff values obtained from a ROC analysis. AUC were calculated to evaluate diagnostic accuracy of each imaging predictor. Two-tailed p < 0.05 was considered statistically significant.
Conclusions
This pilot study of radiogenomic analysis revealed that CT imaging traits may noninvasively predict the TCGA subtype of gastric cancer. In our study, the acute tumor transition angle is the most accurate predictor of the CIN status of gastric cancer, which may provide a preliminary roadmap for personalized medicine. 
Conflicts of Interest:
The authors declare no conflict of interest. Table A1 . List of studied 409 oncogenes and tumor suppressor genes. ABL1  BIRC2  COL1A1  ERCC4  GDNF  JUN  MDM4  NOTCH4 PMS1  SDHD  TLR4  ABL2  BIRC3  CRBN  ERCC5  GNA11  KAT6A  MEN1  NPM1  PMS2  9-Sep  TLX1  ACVR2A  BIRC5  CREB1  ERG  GNAQ  KAT6B  MET  NRAS  POT1  SETD2  TNFAIP3  ADAMTS20 BLM  CREBBP  ESR1  GNAS  KDM5C  MITF  NSD1  POU5F1  SF3B1  TNFRSF14  AFF1  BLNK  CRKL  ETS1  GPR124  KDM6A  MLH1  NTRK1  PPARG  SGK1  TNK2  AFF3  BMPR1A CRTC1  ETV1  GRM8  KDR  MLLT10  NTRK3  PPP2R1A SH2D1A TOP1  AKAP9  BRAF  CSF1R  ETV4  GUCY1A2 KEAP1  MMP2  NUMA1  PRDM1  SMAD2  TP53  AKT1  BRD3  CSMD3  EXT1  HCAR1  KIT  MN1  NUP214  PRKAR1A SMAD4  TPR  AKT2  BRIP1  CTNNA1 EXT2  HIF1A  KLF6  MPL  NUP98  PRKDC  SMARCA4 TRIM24  AKT3  BTK  CTNNB1 EZH2  HLF  KMT2A  MRE11A PAK3  PSIP1  SMARCB1 TRIM33  ALK  BUB1B  CYLD  FANCA  HNF1A  KMT2C  MSH2  PALB2  PTCH1  SMO  TRIP11  AMER1  CARD11  CYP2C19 FANCC  HOOK3  KMT2D  MSH6  PARP1  PTEN  SMUG1  TRRAP  APC  CASC5  CYP2D6  FANCD2  HRAS  KRAS  MTOR  PAX3  PTGS2  SOCS1  TSC1  AR  CBL  DAXX  FANCF  HSP90AA1 LAMP1  MTR  PAX5  PTPN11  SOX11  TSC2  ARID1A  CCND1  DCC  FANCG  HSP90AB1 LCK  MTRR  PAX7  PTPRD  SOX2  TSHR  ARID2  CCND2  DDB2  FAS  ICK  LIFR  MUC1  PAX8  PTPRT  SRC  UBR5  ARNT  CCNE1  DDIT3  FBXW7  IDH1  LPHN3  MUTYH  PBRM1  RAD50  SSX1  UGT1A1  ASXL1  CD79A  DDR2  FGFR1  IDH2  LPP  MYB  PBX1  RAF1  STK11  USP9X  ATF1  CD79B  DEK  FGFR2  IGF1R  LRP1B  MYC  PDE4DIP RALGDS STK36  VHL  ATM  CDC73  DICER1  FGFR3  IGF2  LTF  MYCL  PDGFB  RARA  SUFU  WAS  ATR  CDH1  DNMT3A FGFR4  IGF2R  LTK  MYCN  PDGFRA RB1  SYK  WHSC1  ATRX  CDH11  DPYD  FH  IKBKB  MAF  MYD88  PDGFRB RECQL4  SYNE1  WRN  AURKA  CDH2  DST  FLCN  IKBKE  MAFB  MYH11  PER1  REL  TAF1  WT1  AURKB  CDH20  EGFR  FLI1  IKZF1  MAGEA1 MYH9  PGAP3  RET  TAF1L  XPA  AURKC  CDH5  EML4  FLT1  IL2  MAGI1  NBN  PHOX2B RHOH  TAL1  XPC  AXL  CDK12  EP300  FLT3  IL21R  MALT1  NCOA1  PIK3C2B RNASEL TBX22  XPO1  BAI3  CDK4  EP400  FLT4  IL6ST  MAML2  NCOA2  PIK3CA  RNF2  TCF12  XRCC2  BAP1  CDK6  EPHA3  FN1  IL7R  MAP2K1 NCOA4  PIK3CB  RNF213  TCF3  ZNF384  BCL10  CDK8  EPHA7  FOXL2  ING4  MAP2K2 NF1  PIK3CD  ROS1  TCF7L1  ZNF521  BCL11A  CDKN2A EPHB1  FOXO1  IRF4  MAP2K4 NF2  PIK3CG  RPS6KA2 TCF7L2  BCL11B  CDKN2B EPHB4  FOXO3  IRS2  MAP3K7 NFE2L2  PIK3R1  RRM1  TCL1A  BCL2  CDKN2C EPHB6  FOXP1  ITGA10  MAPK1  NFKB1  PIK3R2  RUNX1  TET1  BCL2L1  CEBPA  ERBB2  FOXP4  ITGA9  MAPK8  NFKB2  PIM1  RUNX1T1 TET2  BCL2L2  CHEK1  ERBB3  FZR1  ITGB2  MARK1  NIN  PKHD1  SAMD9  TFE3  BCL3  CHEK2  ERBB4  G6PD  ITGB3  MARK4  NKX2-1  PLAG1  SBDS  TGFBR2  BCL6  CIC  ERCC1  GATA1  JAK1  MBD1  NLRP1  PLCG1  SDHA  TGM7  BCL9  CKS1B  ERCC2  GATA2  JAK2  MCL1  NOTCH1 PLEKHG5 SDHB  THBS1  BCR  CMPK1  ERCC3  GATA3  JAK3  MDM2  NOTCH2 PML  SDHC  TIMP3 
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